Pediatrix Medical Group, Inc. (NYSE:MD) Stock Holdings Increased by Everence Capital Management Inc.

Everence Capital Management Inc. raised its holdings in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 7.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,840 shares of the company’s stock after buying an additional 960 shares during the period. Everence Capital Management Inc.’s holdings in Pediatrix Medical Group were worth $182,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. Quest Partners LLC lifted its position in shares of Pediatrix Medical Group by 25.6% during the 3rd quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock valued at $35,000 after acquiring an additional 622 shares during the last quarter. Quarry LP raised its stake in Pediatrix Medical Group by 54.1% during the 3rd quarter. Quarry LP now owns 4,735 shares of the company’s stock valued at $55,000 after purchasing an additional 1,662 shares during the period. Canada Pension Plan Investment Board acquired a new stake in Pediatrix Medical Group during the 2nd quarter worth about $72,000. CWM LLC grew its position in Pediatrix Medical Group by 134.0% during the third quarter. CWM LLC now owns 6,427 shares of the company’s stock valued at $74,000 after purchasing an additional 3,681 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Pediatrix Medical Group during the 2nd quarter valued at $81,000. Institutional investors and hedge funds own 97.71% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft lifted their price target on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a report on Monday, November 4th. Truist Financial lowered their target price on shares of Pediatrix Medical Group from $16.00 to $15.00 and set a “hold” rating on the stock in a research report on Monday. StockNews.com upgraded shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research note on Thursday. Mizuho increased their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research note on Tuesday, November 19th. Finally, Macquarie began coverage on Pediatrix Medical Group in a research report on Monday, December 16th. They issued an “outperform” rating and a $18.00 price objective for the company. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $16.25.

Pediatrix Medical Group Price Performance

NYSE:MD opened at $12.73 on Friday. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -4.16, a PEG ratio of 2.00 and a beta of 1.58. The company has a 50-day moving average of $14.35 and a 200-day moving average of $11.54. Pediatrix Medical Group, Inc. has a 52 week low of $6.62 and a 52 week high of $16.41. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The firm had revenue of $511.20 million for the quarter, compared to analysts’ expectations of $498.87 million. During the same period in the prior year, the business posted $0.29 earnings per share. The business’s revenue was up .9% compared to the same quarter last year. As a group, equities research analysts anticipate that Pediatrix Medical Group, Inc. will post 1.26 earnings per share for the current fiscal year.

Insider Transactions at Pediatrix Medical Group

In other news, Director Mark S. Ordan sold 27,600 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total transaction of $423,660.00. Following the transaction, the director now directly owns 138,683 shares in the company, valued at approximately $2,128,784.05. This represents a 16.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Mary Ann E. Moore sold 8,108 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $16.00, for a total transaction of $129,728.00. Following the completion of the transaction, the executive vice president now owns 135,810 shares of the company’s stock, valued at $2,172,960. This trade represents a 5.63 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.00% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.